The ICH Q2(R2) guideline, formally titled “Validation of Analytical Procedures” and revised in 2022, supersedes the original Q2(R1) text from 2005. It provides a harmonised framework for demonstrating that an analytical procedure is suitable for its intended purpose — whether identifying a substance, quantifying an impurity, or measuring assay content in a finished dosage form. The revision was driven by the need to address modern analytical techniques, including chromatographic and spectroscopic methods that have become standard in pharmaceutical quality control laboratories worldwide.
The guideline defines a set of validation characteristics. Specificity requires demonstrating that the method can unequivocally assess the analyte in the presence of expected interferences — degradants, process impurities, excipients and matrix components. For chromatographic methods, this is typically demonstrated through forced-degradation studies (acid, base, oxidative, thermal and photolytic stress) that produce resolved peaks for each degradation product. Peak purity assessment using photodiode-array detection or mass spectrometry further supports the specificity claim.
Linearity and range are established by preparing a minimum of five concentration levels across the specified range and demonstrating a correlation coefficient, y-intercept, slope and residual sum of squares that meet pre-defined acceptance criteria. The ICH Q2(R2) revision emphasises that linearity should be evaluated using visual inspection of a plot and appropriate statistical tests, rather than relying solely on the correlation coefficient. The accuracy of the method is assessed by spiking known quantities of analyte into the sample matrix and measuring recovery across at least three concentration levels (typically 80%, 100% and 120% of the target concentration for assay methods).
Precision encompasses repeatability (intra-assay variation), intermediate precision (inter-day, inter-analyst, inter-instrument variation) and, where applicable, reproducibility (multi-laboratory studies). The acceptable limits depend on the method type and the regulatory expectations for the product. For assay methods, a relative standard deviation (RSD) of 2% or less for repeatability is typical. Detection limit (LOD) and quantitation limit (LOQ) are particularly important for impurity methods, where the ability to detect and accurately quantify low-level impurities directly impacts the safety profile of the drug product.
The revised guideline also introduces updated thinking on robustness, recognising that a systematic evaluation of method robustness during development (using design-of-experiments approaches, for example) can reduce the need for revalidation when minor changes occur in the analytical environment. Risk-based approaches, aligned with ICH Q9 (Quality Risk Management) and ICH Q14 (Analytical Procedure Development), are now explicitly referenced. This integration reflects the broader industry trend toward lifecycle management of analytical methods, where continuous improvement and enhanced process understanding replace the traditional “validate once, use forever” paradigm.
For pharmaceutical manufacturers, compliance with ICH Q2(R2) is not merely a regulatory checkbox — it underpins the reliability of every batch release decision, every stability data point and every bioequivalence comparison. At Espandiar, our analytical development teams apply Q2(R2) principles from the earliest stages of method development, using Quality by Design (QbD) tools to build robustness into methods before they enter the formal validation protocol. This approach reduces development timelines, minimises out-of-specification investigations and ensures that our products consistently meet the highest quality standards across all markets.
Monoclonal antibodies (mAbs) are among the most complex molecules routinely manufactured as pharmaceutical products. Unlike small-molecule drugs, which can be fully characterised by a defined chemical structure, a mAb is a heterogeneous mixture of closely related molecular variants arising from post-translational modifications, charge variants, glycoforms and size variants. Regulatory authorities worldwide — including the FDA, EMA and WHO — require that this heterogeneity be thoroughly characterised and controlled, using a combination of orthogonal analytical techniques that together define the “quality profile” of the molecule.
Peptide mapping is the cornerstone of primary structure confirmation. The mAb is enzymatically digested (typically with trypsin) and the resulting peptides are separated by reversed-phase liquid chromatography and detected by high-resolution mass spectrometry. This technique confirms the amino acid sequence, identifies post-translational modifications (such as oxidation of methionine residues or deamidation of asparagine), and can detect sequence variants that arise from mistranslation or genetic drift in the production cell line. Peptide mapping is required by ICH Q6B for all recombinant therapeutic proteins.
Glycan profiling addresses the carbohydrate structures attached to the Fc region of the antibody at the conserved N-glycosylation site (Asn297 in the CH2 domain). Glycosylation is a critical quality attribute because it affects effector functions — antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and anti-inflammatory activity. Glycan profiles are typically generated by releasing N-glycans with PNGase F, labelling with a fluorescent tag (2-AB or 2-AA) and separating by hydrophilic interaction liquid chromatography (HILIC) or capillary electrophoresis. The relative abundances of major glycoforms (G0F, G1F, G2F, afucosylated species, high-mannose and sialylated forms) are monitored as release and stability-indicating attributes.
Charge variant analysis separates the mAb into acidic, main and basic species using cation-exchange chromatography (CEX) or capillary isoelectric focusing (cIEF). Acidic variants often result from deamidation, sialylation or glycation, while basic variants can arise from C-terminal lysine clipping, N-terminal pyroglutamate formation or aggregation. Because charge variants can affect pharmacokinetics, potency and immunogenicity, they are tightly controlled within predefined specification ranges. Similarly, aggregation testing — by size-exclusion chromatography (SEC) or analytical ultracentrifugation — quantifies monomer content and higher-order aggregates, which are of particular concern due to their potential to trigger immunogenic responses in patients.
Together, these techniques form a multi-attribute analytical strategy that provides a comprehensive picture of mAb quality. Espandiar applies this approach across its biotechnology division, integrating advanced mass spectrometry, chromatography and electrophoresis platforms to ensure that every batch of monoclonal antibody meets the exacting standards required for global regulatory submission and patient safety.
Lipid nanoparticles (LNPs) have emerged as the leading delivery system for nucleic acid therapeutics, most visibly demonstrated by the mRNA COVID-19 vaccines. However, the science of LNP-mediated delivery extends far beyond vaccines — it encompasses siRNA therapeutics, mRNA-based protein replacement, gene editing payloads and in vivo gene therapy. Understanding the structure-function relationships of LNPs is essential for any pharmaceutical organisation working in the nucleic acid space.
A modern LNP formulation typically contains four lipid components, each serving a distinct function. The ionizable lipid (often referred to as the “active” lipid) is the most critical component. At physiological pH (7.4), the lipid is electrically neutral, which minimises toxicity and maximises circulation time. Upon endocytosis and exposure to the acidic environment of the endosome (pH ~5.5–6.5), the lipid becomes protonated, enabling it to interact with the anionic phospholipids of the endosomal membrane and facilitate escape of the nucleic acid cargo into the cytoplasm. The pKa of the ionizable lipid — optimally in the range of 6.2–6.5 — is the single most important predictor of in vivo potency.
The structural phospholipid (typically DSPC — distearoylphosphatidylcholine) provides bilayer stability and contributes to the lamellar structure of the particle. The cholesterol component modulates membrane fluidity, reduces drug leakage during storage and circulation, and enhances endosomal escape efficiency. Finally, the PEG-lipid (a lipid conjugated to polyethylene glycol) forms a hydrophilic “stealth” corona on the particle surface, reducing opsonisation and clearance by the mononuclear phagocyte system, thereby extending plasma half-life. The molar ratio of PEG-lipid is critical: too little leads to rapid clearance, while too much can inhibit cellular uptake and endosomal escape.
LNP manufacturing employs microfluidic mixing — typically a T-junction or staggered herringbone micromixer — in which an ethanolic solution of the lipid mixture is rapidly mixed with an aqueous buffer containing the nucleic acid at a precisely controlled flow-rate ratio. The rapid dilution of ethanol triggers spontaneous nanoprecipitation, trapping the nucleic acid inside the forming particle. Critical quality attributes include particle size (typically 60–100 nm by dynamic light scattering), polydispersity index (PDI < 0.15), encapsulation efficiency (>90%), zeta potential and lipid composition (by HPLC-CAD). Process parameters — flow rate, total flow rate, lipid concentration, aqueous-to-organic phase ratio and mixing temperature — are optimised using Quality by Design principles aligned with ICH Q8.
Characterisation of LNPs poses unique analytical challenges. Encapsulated vs. free nucleic acid is quantified by a modified RiboGreen assay. Lipid composition is assessed by reversed-phase HPLC with charged aerosol detection (CAD). Morphology is examined by cryo-electron microscopy. Stability studies must evaluate both physical stability (particle growth, aggregation) and chemical stability (lipid hydrolysis, oxidation) under ICH Q1A-recommended conditions. At Espandiar, our formulation scientists are actively advancing LNP platform technologies to support our expanding nucleic acid therapeutic pipeline.
Adaptive clinical trial designs represent a paradigm shift from the traditional fixed-sample approach to drug development. Defined by the FDA guidance (2019) and the EMA reflection paper (2007, updated 2023), an adaptive design is one that allows prospectively planned modifications to one or more aspects of the trial — such as sample size, randomisation ratios, treatment arms, or eligibility criteria — based on accumulating data from the trial itself, without undermining the trial’s integrity and validity.
The most commonly used adaptive designs include group sequential designs, which allow for interim analyses with pre-specified stopping boundaries for efficacy or futility; sample-size re-estimation, in which the total sample size is adjusted based on the observed effect size or variability at an interim look; adaptive randomisation, which shifts allocation ratios to favour the better-performing arm; and seamless Phase II/III designs, which combine the dose-selection objectives of Phase II with the confirmatory objectives of Phase III into a single trial, eliminating the operational gap between phases.
Master protocols — including basket trials, umbrella trials and platform trials — extend the adaptive framework further. A basket trial evaluates a single targeted therapy across multiple disease indications that share a common molecular feature (e.g., a BRAF V600E mutation). An umbrella trial evaluates multiple targeted therapies within a single disease indication, each matched to a specific biomarker-defined subgroup. A platform trial is a continuous, multi-arm trial designed to add or remove treatment arms over time, sharing a common control arm. These designs are particularly valuable in oncology and rare diseases, where patient populations are small and the number of promising compounds is large.
The statistical foundation of adaptive designs requires careful consideration of type I error control. Because multiple interim analyses and design modifications inflate the probability of a false-positive result, adaptive designs employ group-sequential boundaries (O’Brien-Fleming, Pocock, or Lan-DeMets alpha-spending functions), combination tests (e.g., the inverse-normal method) or conditional error functions to maintain the overall significance level at the pre-specified alpha (typically 0.025 one-sided). Simulation studies are essential during the planning phase to evaluate the operating characteristics of the design under a range of assumed treatment effects.
Espandiar’s clinical development teams leverage adaptive designs across our oncology, neurology and rare disease programs. By integrating digital biomarkers, model-informed drug development (MIDD) and real-world evidence, we design trials that are more efficient, more ethical and more likely to deliver definitive answers — ultimately accelerating access to new medicines for patients who need them.
The European Commission’s revised EU GMP Annex 1, titled “Manufacture of Sterile Medicinal Products,” entered into force on 25 August 2023, with a transition period extending to 25 August 2024 for existing manufacturing operations. The revision — the most comprehensive since the original 1972 text — represents a fundamental shift in how regulatory authorities expect sterile manufacturers to design, operate and assure the quality of their processes. The document grew from 16 pages to approximately 60 pages, reflecting the depth and breadth of the changes.
The centrepiece of the revision is the concept of a Contamination Control Strategy (CCS). The CCS is a documented, holistic approach to contamination risk that integrates facility design, equipment selection, environmental monitoring, personnel training, process design, cleaning and sanitisation, and quality system oversight. The CCS must be based on a formal Quality Risk Management (QRM) process per ICH Q9, using tools such as failure mode and effects analysis (FMEA), fault tree analysis or Ishikawa diagrams to identify, evaluate and mitigate contamination risks. The CCS is not a static document — it must be reviewed and updated throughout the product lifecycle, particularly when changes occur in the facility, equipment, process or product.
Major changes to barrier technology requirements reflect advances in aseptic processing. The revised text elevates the role of Restricted Access Barrier Systems (RABS) and isolators, and introduces enhanced expectations for the qualification and monitoring of these systems. VHP (vapourised hydrogen peroxide) decontamination cycle development must now include aeration validation and residue limits. The concept of “Grade A with unidirectional airflow” is reinforced, with specific requirements for air velocity, recovery time and particle monitoring. The revision also addresses the growing use of robotics and automation in aseptic processing, recognising their role in reducing human intervention — the primary risk factor for microbial contamination.
The revised Annex 1 places greater emphasis on environmental monitoring (EM) as a process monitoring tool rather than a mere compliance exercise. Viable and non-viable particle monitoring must be risk-based, with the frequency, duration and location of monitoring determined by the CCS. Trending and data analysis are now explicit requirements, with the expectation that manufacturers will use statistical process control methods to detect adverse trends before they result in out-of-specification events. The document also addresses the limitations of traditional settle plates and active air samplers, and encourages the adoption of rapid microbiological methods where justified.
At Espandiar, our quality assurance and manufacturing teams have completed comprehensive gap analyses against the revised Annex 1 requirements across all sterile manufacturing sites. The CCS framework has been implemented, and enhanced monitoring, barrier technology and QRM processes are fully operational. These investments ensure that our sterile manufacturing capabilities continue to meet the highest global standards — protecting both product quality and patient safety.
Green chemistry, as articulated by Paul Anastas and John Warner in their foundational 12 Principles (1998), provides a framework for designing chemical processes that reduce or eliminate the use and generation of hazardous substances. In pharmaceutical manufacturing — and particularly in the synthesis of active pharmaceutical ingredients (APIs) — the application of green chemistry principles has become both a regulatory expectation and a competitive differentiator, driven by increasing environmental regulations, supply-chain pressures and corporate sustainability commitments.
Atom economy, the second of the 12 Principles, measures the efficiency with which reactant atoms are incorporated into the final product. Traditional pharmaceutical syntheses often have poor atom economies, with significant mass lost to stoichiometric by-products, protecting groups and reagents. Modern synthetic route design prioritises catalytic reactions (which have near-ideal atom economy), telescoped processes (which eliminate intermediate isolation steps) and convergent syntheses (which reduce the number of linear steps). A well-designed API synthesis route should target an overall step count below 10 and a process mass intensity (PMI) below 50 — though the most advanced green processes achieve PMIs below 20.
Solvent selection is one of the most impactful decisions in API synthesis, as solvents typically account for 80–90% of the total mass used in a manufacturing process. The CHEM21 solvent selection guide and the GSK solvent sustainability guide provide practical frameworks for choosing solvents based on safety, environmental impact and process suitability. The industry is moving away from Class 1 and Class 2 solvents (per ICH Q3C) — such as benzene, carbon tetrachloride, dichloromethane and N,N-dimethylformamide — toward safer alternatives including ethanol, 2-methyltetrahydrofuran (2-MeTHF, derived from renewable resources), cyclopentyl methyl ether (CPME) and water. Solvent recovery and recycling systems are now standard practice at API manufacturing facilities.
Biocatalysis has emerged as a powerful tool for green API synthesis. Enzymes — including ketoreductases, transaminases, cytochrome P450 monooxygenases, lipases and nitrilases — offer exquisite chemo-, regio- and stereoselectivity under mild conditions (aqueous, ambient temperature, neutral pH), eliminating the need for protecting groups and harsh reagents. Advances in directed evolution, high-throughput screening and computational enzyme design have dramatically expanded the substrate scope and operational robustness of biocatalysts, making them viable at manufacturing scale. Notable industrial examples include the sitagliptin synthesis (Merck/Codexis), which replaced a rhodium-catalysed asymmetric hydrogenation with a transaminase, reducing waste by 76%.
At Espandiar, our API manufacturing division integrates green chemistry principles across the product lifecycle. From route selection during development through commercial manufacturing, we optimise for atom economy, solvent minimisation, energy efficiency and waste reduction. Our recently commissioned zero-liquid-discharge (ZLD) wastewater treatment system at our largest API facility eliminates liquid effluent discharge entirely, and our green chemistry metrics — PMI, E-factor, solvent recovery rate and carbon intensity — are tracked and reported as part of our corporate sustainability framework aligned with GRI and SASB standards.
Espandiar Pharmaceuticals announced today that new translational data from its Phase II precision oncology program will be presented at the upcoming International Congress of Clinical Oncology (ICCO) in Vienna. The data describe biomarker-selected response patterns in patients with advanced solid tumours harbouring specific genomic alterations, providing critical insights into the molecular determinants of treatment response and resistance.
The Phase II study enrolled 247 patients across 38 sites in 12 countries, using a biomarker-enriched design that selected patients based on next-generation sequencing (NGS) of tumour tissue. The primary endpoint — objective response rate (ORR) by RECIST v1.1 — was met in the pre-specified biomarker-positive cohort, with a confirmed ORR of 38.5% and a median duration of response of 11.2 months. Subgroup analyses revealed particularly promising activity in patients with KRAS G12C-mutant non-small cell lung cancer (ORR 47.2%) and HER2-amplified gastro-oesophageal adenocarcinoma (ORR 41.8%).
“These data represent a significant step forward in our understanding of how molecular profiling can be used to match the right patient to the right therapy,” said Dr. Elena Vasquez, Espandiar’s Chief Medical Officer. “The biomarker-selected response patterns we observed will directly inform the design of our planned Phase III program, which is expected to initiate enrolment in the first half of 2026.”
The translational research component of the study, conducted in collaboration with academic partners at the Dana-Farber Cancer Institute and the Karolinska Institute, included comprehensive pharmacodynamic profiling, circulating tumour DNA (ctDNA) analysis and single-cell RNA sequencing of pre- and post-treatment biopsies. These data are expected to be published in a peer-reviewed journal in the third quarter of 2025.
Espandiar Pharmaceuticals has published its 2024 Sustainability Impact Report, documenting measurable progress against its science-aligned environmental targets and outlining the company’s pathway to net-zero Scope 1 and 2 greenhouse gas emissions by 2035. The report, prepared in accordance with the Global Reporting Initiative (GRI) Standards, the Sustainability Accounting Standards Board (SASB) Pharmaceutical Biotechnology & Life Sciences framework, and the recommendations of the Task Force on Climate-related Financial Disclosures (TCFD), provides a comprehensive view of Espandiar’s environmental, social and governance (ESG) performance.
Key environmental metrics for 2024 include a 42% reduction in operational carbon emissions (Scope 1 and 2) against the 2019 baseline, 76% of electricity sourced from renewable energy across global operations, and a 35% reduction in water consumption per unit of production. The report also details the commissioning of the zero-liquid-discharge (ZLD) wastewater treatment system at the company’s largest API manufacturing facility, which eliminates liquid effluent discharge and recovers over 95% of process water for reuse.
“Our sustainability strategy is grounded in science and driven by accountability,” said Marcus Lindberg, Espandiar’s Chief Sustainability Officer. “The progress documented in this report reflects the commitment of our 6,800 colleagues worldwide to integrating environmental responsibility into every decision — from solvent selection in API synthesis to renewable energy procurement for our manufacturing sites.”
The 2024 report also introduces Espandiar’s updated Scope 3 emissions reduction targets, addressing the full value chain from raw material sourcing through product distribution and end-of-life. The company has committed to engaging its top 50 suppliers (representing approximately 70% of Scope 3 emissions) in science-based target-setting by 2027, and to achieving a 30% reduction in Scope 3 emissions intensity by 2035.
Espandiar Pharmaceuticals reported financial results for the first quarter ended 31 March 2025 and provided a comprehensive pipeline update across its oncology, neurology and rare disease programs. Total revenue for the quarter was EUR 892 million, representing 14% growth year-over-year, driven by strong demand for the company’s specialty medicines portfolio and continued expansion of its CDMO services segment.
Research and development investment for the quarter was EUR 217 million, representing 24.3% of revenue and consistent with the company’s long-term commitment to investing in innovative science. Key pipeline milestones during the quarter included the initiation of a Phase III study in the precision oncology program, the completion of enrolment in a Phase II study in a rare neurodegenerative disease, and the filing of an IND/CTA for a novel biologic in immunology.
“We delivered a strong first quarter, with double-digit revenue growth and meaningful clinical progress across our portfolio,” said James Thornton, Espandiar’s Chief Financial Officer. “We are reaffirming our full-year guidance for R&D investment of approximately EUR 900 million and capital expenditure of approximately EUR 350 million, reflecting our confidence in the long-term value creation potential of our pipeline.”
The company’s net cash position at 31 March 2025 was EUR 1.8 billion, providing substantial financial flexibility to fund ongoing clinical programs, pursue strategic acquisitions and invest in manufacturing capacity expansion. Espandiar reaffirmed its commitment to returning capital to shareholders through its existing share buyback programme, with EUR 100 million of repurchases authorised for the full year 2025.
Espandiar announced the successful qualification of a new aseptic fill-finish line at its European manufacturing campus in Cork, Ireland. The facility, which represents a capital investment of EUR 120 million, expands Espandiar’s CDMO capacity for vials, pre-filled syringes and cartridges and is designed to comply fully with the revised EU GMP Annex 1 (2023) requirements.
The new line features a state-of-the-art restricted access barrier system (RABS) with integrated vapourised hydrogen peroxide (VHP) decontamination, unidirectional airflow meeting ISO 5 (Grade A) conditions, and real-time environmental monitoring using a network of viable and non-viable particle counters. The filling equipment is capable of processing vials (2R to 50R), pre-filled syringes (0.5 mL to 5 mL) and cartridges (1 mL to 3 mL) at speeds of up to 400 units per minute, with in-process check-weighing, vision inspection and automatic reject systems.
“This capacity expansion directly addresses the growing demand from our biopharmaceutical partners for high-quality, EU-manufactured sterile products,” said Dr. Anna Kowalski, Head of CDMO Operations at Espandiar. “The facility has been designed from the ground up to meet the highest regulatory expectations, including the new Contamination Control Strategy requirements of EU GMP Annex 1. We are now accepting commercial orders for fill-finish campaigns starting in Q3 2025.”
The qualification programme included installation qualification (IQ), operational qualification (OQ) and performance qualification (PQ), as well as media fill trials demonstrating aseptic process capability. All qualification activities were completed within the planned timeline, and the facility has been inspected and approved by the Irish Health Products Regulatory Authority (HPRA). The expansion brings Espandiar’s total sterile fill-finish capacity across its global network to approximately 200 million units per year.
Espandiar’s Computational Chemistry division has deployed the second generation of its proprietary AI-assisted lead optimization platform, codenamed “Meridian 2.0.” The updated platform integrates advances in generative chemistry, active-learning experimental loops and multi-objective optimization to significantly accelerate the identification of clinical candidate molecules across the company’s discovery programs.
Meridian 2.0 builds on the foundation of the first-generation platform, which has been in use since 2021 and has contributed to the advancement of 14 preclinical programs. Key enhancements include a diffusion-model-based molecular generator capable of designing novel chemical scaffolds that satisfy multiple property constraints simultaneously — including potency, selectivity, metabolic stability, solubility and predicted safety profiles. The generative model has been trained on Espandiar’s internal compound library (over 2.3 million structures) and fine-tuned using activity data from high-throughput screening campaigns.
The platform’s active-learning loop — which iteratively selects the most informative compounds for synthesis and testing, then updates the predictive models with the new data — has reduced the average lead optimization cycle time from 18 months to approximately 11 months for early-stage programs. This acceleration is achieved by prioritising synthesis of compounds that maximize information gain, rather than those that simply maximise predicted activity. Multi-objective Bayesian optimization balances competing objectives (potency vs. safety, for example) and identifies Pareto-optimal candidates that would be difficult to find through traditional medicinal chemistry approaches alone.
“Meridian 2.0 represents a step change in how we do lead optimization,” said Prof. Henrik Larsson, VP of Computational Chemistry at Espandiar. “By closing the loop between in silico prediction and experimental validation, we are making better decisions faster, with fewer synthesis cycles and a higher probability of identifying truly differentiated clinical candidates.”
Espandiar Pharmaceuticals has announced the launch of an expanded postdoctoral fellowship programme, offering two-year research positions in computational biology, bioprocessing and formulation science. The programme, now in its fourth year, has been expanded from 8 to 14 positions and includes new partnerships with the University of Cambridge, the Karolinska Institute, MIT and the National University of Singapore.
Fellows will be embedded within Espandiar’s R&D teams and will work on translational research projects that bridge academic discovery and pharmaceutical development. The computational biology track will focus on applying machine learning to multi-omics data integration for target identification and biomarker discovery. The bioprocessing track will investigate advanced process analytical technology (PAT) tools for real-time monitoring and control of biologic manufacturing processes. The formulation science track will explore novel drug delivery systems, including lipid nanoparticles, polymeric micelles and long-acting injectable formulations.
“Our postdoctoral fellowship programme is a cornerstone of our talent strategy and a powerful mechanism for bringing fresh scientific perspectives into our R&D organisation,” said Dr. Sarah Chen, VP of Human Resources and Organisational Development at Espandiar. “We are proud that over 60% of our previous fellows have transitioned into permanent research roles at Espandiar, and we expect this expanded cohort to contribute meaningfully to our pipeline.”
Applications for the 2025–2027 fellowship cohort are now open, with a deadline of 30 June 2025. Fellows receive a competitive salary, access to Espandiar’s state-of-the-art research facilities and computational infrastructure, a dedicated industry mentor, and a professional development budget for conference attendance and training. More information is available on the Careers section of espandiar.com.
Espandiar has commissioned a new zero-liquid-discharge (ZLD) wastewater treatment system at its largest API manufacturing facility, located in Telangana, India. The system, which represents a capital investment of approximately EUR 35 million, eliminates liquid effluent discharge from the facility and recovers over 95% of process water for reuse in manufacturing operations.
The ZLD system employs a multi-stage treatment train comprising pre-treatment (chemical precipitation, dissolved air flotation and pH adjustment), ultrafiltration, reverse osmosis (two-pass), and a mechanical vapour recompression (MVR) crystalliser for final concentration of the reject stream. The recovered permeate meets USP Purified Water specifications and is fed back into the facility’s water system for use in synthesis, crystallisation and cleaning operations. The crystallised solids — primarily inorganic salts and concentrated organic residues — are sent to an approved hazardous waste contractor for disposal in compliance with local and international regulations.
Commissioning of the ZLD system is a key milestone in Espandiar’s water stewardship programme and contributes directly to the company’s sustainability targets. The facility previously discharged approximately 2,500 cubic metres of treated wastewater per day. With the ZLD system operational, this discharge has been reduced to zero, and the facility’s freshwater consumption is expected to decrease by approximately 30% through water recycling. The environmental benefit is particularly significant given that the facility is located in a region classified as water-stressed by the World Resources Institute.
“This investment demonstrates our commitment to responsible manufacturing in the communities where we operate,” said Rajesh Patel, Site Director for Espandiar’s Telangana facility. “Eliminating liquid effluent discharge while simultaneously reducing freshwater consumption is a win for the environment, for the local community and for our business. We believe this system sets a new benchmark for API manufacturing in the region.”
Espandiar has announced the peer-reviewed publication of preclinical pharmacology and toxicology data supporting an upcoming Investigational New Drug (IND) / Clinical Trial Authorisation (CTA) filing for a rare disease program targeting lysosomal storage disorder (LSD). The data, published in Nature Communications, describe target engagement, dose-exposure-response relationships, and preclinical safety margins for ESP-4821, a novel enzyme replacement therapy engineered for enhanced cellular uptake and extended tissue half-life.
ESP-4821 is a recombinant human enzyme conjugated to a proprietary glycan-targeting moiety that directs the enzyme to the mannose-6-phosphate receptor (M6PR) on the surface of affected cells. In preclinical disease models, ESP-4821 demonstrated superior tissue distribution and intracellular enzyme activity compared to the current standard of care, with a 3.8-fold increase in enzyme activity in the brain parenchyma — a critical advantage for LSDs with central nervous system involvement. Dose-exposure-response modelling established a clear pharmacokinetic-pharmacodynamic relationship, enabling the selection of a first-in-human dose with a predicted therapeutic index of greater than 20-fold.
The toxicology programme, conducted in two species in compliance with GLP, demonstrated a favourable safety profile at doses up to 50 times the anticipated therapeutic exposure. No treatment-related adverse findings were observed in clinical pathology, histopathology or functional observational battery assessments. Immunogenicity was low, with no anti-drug antibodies detected at any dose level in the 26-week repeat-dose study.
“The publication of these data in a high-impact journal is a testament to the quality and rigour of our rare disease research programme,” said Dr. Maria Fernandez, Head of Rare Disease Research at Espandiar. “We are now finalising our IND/CTA submission and look forward to initiating the first clinical study in patients with this devastating condition. Rare disease patients deserve the same quality of science and urgency of development as any other patient population.”
Espandiar Pharmaceuticals has joined the Advanced Therapies Alliance (ATA), a multi-company, pre-competitive consortium focused on addressing shared scientific and regulatory challenges in advanced therapy medicinal products (ATMPs), including cell therapies, gene therapies and tissue-engineered products. The ATA, founded in 2022, now includes 14 pharmaceutical and biotechnology companies, 6 academic research centres and 4 regulatory science organisations.
The consortium’s work programme addresses three priority areas. First, the development of harmonised analytical methods and reference standards for the characterisation of viral vectors, gene-modified cells and genome-editing constructs — a critical need given the diversity and complexity of ATMPs and the current lack of compendial standards. Second, the establishment of shared regulatory science data repositories that enable cross-company benchmarking of CMC (Chemistry, Manufacturing and Controls) strategies for ATMPs, accelerating regulatory submissions by identifying best practices and common approaches. Third, the development of training and education programmes for regulatory agency reviewers, manufacturing staff and quality professionals to build capacity across the ATMP ecosystem.
“The advanced therapy landscape is evolving rapidly, and the scientific and regulatory challenges are too large and too complex for any single company to address alone,” said Dr. Thomas Bergström, Espandiar’s Chief Scientific Officer. “By participating in the ATA, we contribute to and benefit from a shared knowledge base that will ultimately accelerate the development and approval of life-changing therapies for patients with serious diseases. Pre-competitive collaboration is not just good science — it is good medicine.”
Espandiar’s participation in the ATA complements the company’s existing internal ATMP capabilities, which include a dedicated Cell and Gene Therapy unit within its Biotechnology division and a GMP manufacturing suite for viral vector production at its Cork, Ireland campus. The company expects to leverage ATA resources and learnings to support its internal gene therapy programmes in rare genetic diseases.
Espandiar Pharmaceuticals GmbH was formally incorporated on 17 September 2018 in Berlin-Charlottenburg, Germany, by co-founders Dr. Lukas Hartmann (formerly VP of Chemical Biology at Bayer) and Dr. Priya Ramaswamy (formerly a group leader in targeted drug delivery at the Max Planck Institute for Colloids and Interfaces). The company was established with a mission to bridge the gap between academic pharmaceutical research and commercial drug development, with an initial focus on oncology and neurology — two therapeutic areas where unmet medical need remained acute despite decades of research investment.
The founding team was joined by three additional scientific co-founders from the Freie Universität Berlin and the European Molecular Biology Laboratory (EMBL), bringing expertise in computational chemistry, formulation science and regulatory affairs. An initial seed investment of EUR 4.2 million was provided by a syndicate of Berlin-based angel investors and the German Federal Ministry of Education and Research (BMBF) through its GO-Bio initial funding programme, which supports the translation of life-science research into commercially viable products.
“We founded Espandiar on the conviction that the pharmaceutical industry needs new models of drug development — models that are more data-driven, more patient-centric and more agile,” said Dr. Hartmann, who serves as the company’s Chief Executive Officer. “Our vision is to build a fully integrated pharmaceutical company that can take a molecule from computational design through global manufacturing, while maintaining the scientific rigour and translational focus of the best academic research.” The company initially operated from a 600-square-metre laboratory and office space in the Berlin Biotech Park in Buch, with a founding team of 12 scientists and support staff.
Espandiar Pharmaceuticals has opened its first dedicated research laboratory at the Berlin-Buch Biotech Park, a leading life sciences campus that houses over 60 biotechnology companies and academic research institutes. The 800-square-metre facility includes state-of-the-art medicinal chemistry laboratories, a cell biology suite with BSL-2 containment, and a dedicated analytical development laboratory equipped with HPLC, LC-MS, NMR and DSC instrumentation.
The laboratory was designed from the outset to support an integrated drug discovery workflow — from target validation and assay development through hit identification, lead optimization and preclinical candidate selection. A dedicated computational chemistry room houses the company’s GPU-accelerated molecular modelling cluster, which supports structure-based drug design, molecular dynamics simulations and machine-learning-driven property prediction. The facility also includes a small-scale formulation laboratory for early-stage preformulation studies, enabling rapid assessment of the developability of new chemical entities.
“Having our own purpose-built laboratory space is a transformative milestone for Espandiar,” said Dr. Priya Ramaswamy, Chief Scientific Officer and co-founder. “It allows us to establish the standard operating procedures, quality systems and safety culture that will underpin all of our future research and manufacturing activities. The Berlin-Buch ecosystem — with its proximity to the Max Delbrück Center, the Leibniz Institute and the Charité university hospital — provides an unparalleled environment for translational biomedical research.”
Espandiar Pharmaceuticals has closed a EUR 28 million Series A financing round, led by EQT Ventures with participation from Novo Holdings, Versant Ventures and the investment arm of the Berlin-based IBB Beteiligungsgesellschaft. The round, which was oversubscribed, brings the total capital raised by the company to EUR 32 million since its founding in September 2018 and provides a runway of approximately 30 months to advance its lead program through IND-enabling studies and into first-in-human clinical trials.
The proceeds will be allocated across three priority areas. Approximately 55% will fund the advancement of Espandiar’s lead oncology program — a small-molecule inhibitor of a previously undruggable protein-protein interaction involved in DNA damage repair — through GLP toxicology, CMC development and regulatory filing. Approximately 25% will support the expansion of the computational chemistry and AI-driven drug discovery platform, including the hiring of machine learning engineers and the acquisition of high-performance computing infrastructure. The remaining 20% will be used to build out the company’s early-stage pipeline, which at the time of the financing included three additional programs in neurology and immuno-oncology at the hit-to-lead stage.
“Espandiar represents exactly the kind of company we seek to back — a world-class scientific team with a clear translational strategy and a differentiated approach to drug discovery,” said Dr. Sandra Lindqvist, Partner at EQT Ventures, who will join Espandiar’s Board of Directors. “The integration of AI and computational methods into the core of their discovery process, combined with their ambition to build end-to-end capabilities from research through manufacturing, positions them uniquely in the European biotechnology landscape.”
Espandiar’s Research and Development committee has approved the nomination of ESP-101, a first-in-class small-molecule inhibitor of the RAD51-ssDNA interaction, as the company’s first clinical candidate. ESP-101 targets the homologous recombination (HR) DNA repair pathway and is designed to exploit synthetic lethality in tumours with specific homologous recombination deficiency (HRD) profiles — an approach conceptually related to PARP inhibition but targeting a distinct node in the DNA damage response network.
The nomination was supported by a comprehensive preclinical data package demonstrating potent and selective inhibition of RAD51-mediated strand invasion in biochemical and cellular assays (IC50 of 8 nM), strong synergistic activity with DNA-damaging chemotherapeutic agents in HRD patient-derived xenograft (PDX) models, favourable pharmacokinetic properties including oral bioavailability exceeding 65% in multiple species, and a clean safety pharmacology profile in initial in vitro and in vivo studies. The molecule was discovered using Espandiar’s structure-based drug design platform and optimized through 14 iterative design-make-test-analyse cycles informed by co-crystallography data obtained in collaboration with the European Synchrotron Radiation Facility (ESRF) in Grenoble.
“The nomination of ESP-101 as our first clinical candidate is the culmination of two years of focused scientific effort and a powerful validation of our computational chemistry and structural biology capabilities,” said Dr. Thomas Bergström, then Head of Discovery at Espandiar. “We are now moving rapidly into IND-enabling studies, with the goal of filing our first Clinical Trial Application in Europe by the end of 2020. This is a pivotal moment for our team, our investors and, most importantly, for the patients we ultimately aim to serve.”
Espandiar Pharmaceuticals has completed its first formal scientific advice meeting with the European Medicines Agency (EMA), receiving guidance on the proposed clinical development plan for ESP-101, the company’s lead oncology candidate. The meeting, held under the EMA’s Protocol Assistance procedure, addressed the design of the first-in-human study, the proposed biomarker strategy for patient selection, and the requirements for the Chemistry, Manufacturing and Controls (CMC) section of the Clinical Trial Application (CTA).
Key outcomes of the scientific advice included agreement from the Committee for Medicinal Products for Human Use (CHMP) that a biomarker-enriched Phase I dose-escalation design, incorporating circulating tumour DNA (ctDNA) as an exploratory pharmacodynamic biomarker, was appropriate for the program. The CHMP also endorsed the proposed starting dose, based on the FDA’s guidance on estimating the maximum recommended starting dose, and provided recommendations on the frequency and timing of tumour biopsies for pharmacodynamic assessments. On CMC matters, the Agency confirmed that the proposed specifications for the drug substance and drug product aligned with ICH Q6A and Q8(R2) expectations, and that the stability programme should follow ICH Q1A(R2) with long-term and accelerated conditions.
“Receiving constructive guidance from the EMA at this early stage is invaluable,” said Dr. Katrin Becker, VP of Regulatory Affairs at Espandiar. “Scientific advice allows us to align our development plan with regulatory expectations before we invest significant resources in clinical studies. This proactive engagement is a cornerstone of our regulatory strategy and reflects our commitment to developing medicines that meet the highest standards of quality, safety and efficacy.”
Espandiar Pharmaceuticals has dosed the first patient in a Phase I, first-in-human, open-label, dose-escalation study of ESP-101 in patients with advanced solid tumours harbouring homologous recombination deficiency (HRD). The study, designated ESP-101-001, is being conducted at five clinical sites in Germany and the United Kingdom, with plans to expand to additional European sites as the dose-escalation proceeds.
The study employs a modified 3+3 dose-escalation design with an accelerated titration phase at the first two dose levels, followed by standard 3+3 escalation. The primary objectives are to assess the safety and tolerability of ESP-101, to determine the maximum tolerated dose (MTD) and/or the recommended Phase II dose (RP2D), and to characterize the pharmacokinetic profile. Secondary objectives include preliminary assessment of antitumour activity per RECIST v1.1, evaluation of pharmacodynamic biomarkers (including γ-H2AX foci formation in tumour biopsies and ctDNA dynamics in plasma), and exploration of predictive biomarkers of response.
“Dosing the first patient with ESP-101 is a landmark moment for Espandiar and a testament to the dedication of our research, development and manufacturing teams who have worked tirelessly to reach this milestone,” said Dr. Elena Vasquez, Chief Medical Officer. “The transition from a molecule on a computer screen to a medicine in a patient is the most challenging and the most rewarding part of what we do. We are grateful to the patients, investigators and clinical site staff who are participating in this study.”
Espandiar Pharmaceuticals has completed the acquisition of a fully operational active pharmaceutical ingredient (API) manufacturing facility in the Mahape industrial area of Navi Mumbai, India. The facility, previously operated by a mid-size Indian generic manufacturer, includes multipurpose synthesis capabilities with reactor capacities ranging from 500 litres to 5,000 litres, a dedicated hydrogenation suite, isolation and drying equipment, and a quality control laboratory with HPLC, GC, IR, UV and Karl Fischer titration capabilities.
The acquisition represents a strategic move to establish vertical integration of Espandiar’s supply chain and to build a platform for contract development and manufacturing (CDMO) services. The facility has existing approvals from regulatory authorities in India (CDSCO), the United States (FDA) and the European Union (multiple EU GMP certificates issued by the German authorities), providing immediate access to regulated markets. Espandiar plans to invest approximately EUR 12 million over the next 24 months in upgrades including a new solvent recovery system, enhanced HVAC with HEPA filtration, and an expanded quality control laboratory.
“The acquisition of this facility is a foundational step in our strategy to build an end-to-end pharmaceutical enterprise,” said Marcus Lindberg, then COO of Espandiar. “By integrating API manufacturing into our capabilities, we gain control over our supply chain, reduce our dependence on third-party suppliers, and position ourselves to offer CDMO services to partners who need reliable, high-quality API manufacturing at scale. India is the world’s largest producer of generic APIs by volume, and this facility gives us a strategic foothold in that ecosystem.”
In response to the global COVID-19 pandemic, Espandiar Pharmaceuticals has entered into a supply agreement with an international humanitarian procurement agency to manufacture and supply a critical advanced intermediate for an antiviral drug used in the treatment of SARS-CoV-2 infection. The agreement, valued at approximately EUR 8 million, leverages the company’s recently acquired API manufacturing facility in Mumbai to produce the intermediate under accelerated timelines.
The project required rapid process transfer, scale-up and regulatory compliance activities. Espandiar’s process development team in Berlin collaborated with the Mumbai manufacturing team to transfer and optimize the synthetic route, achieving target yield and purity specifications within eight weeks. The quality team expedited the establishment of specifications, analytical methods and stability studies in accordance with ICH Q7 (GMP for Active Pharmaceutical Ingredients), and the batch was released for distribution after meeting all pre-defined acceptance criteria.
“When the world faces a public health emergency, the pharmaceutical industry has a duty to respond quickly and responsibly,” said Dr. Lukas Hartmann, CEO. “Our team in Mumbai demonstrated extraordinary commitment, working around the clock under challenging conditions to deliver this critical material on time. This experience also validated the strength of our integrated manufacturing capabilities and our ability to execute at speed when it matters most.”
Espandiar has completed the construction and qualification of a new synthesis wing at its API manufacturing facility in Mumbai, effectively doubling the site’s production capacity. The EUR 18 million expansion adds six new glass-lined reactors (ranging from 2,000 to 8,000 litres), a dedicated cryogenic reaction capability for low-temperature chemistries, an automated clean-in-place (CIP) system, and a centralized distributed control system (DCS) for process automation and real-time monitoring.
The new wing was designed in accordance with ICH Q7 (GMP for APIs) and EU GMP Part II requirements, with particular attention to containment for potent compound manufacturing. Occupational exposure limit (OEL)-based containment design includes isolators for charging and discharging operations, split butterfly valves on reactor transfers, and continuous liner systems for solid handling. The HVAC system provides cascade pressure differentials between process areas, with temperature and humidity control suitable for moisture-sensitive reactions and crystallizations.
The capacity expansion enables Espandiar to manufacture a broader range of API products at commercial scale and positions the Mumbai facility as a key node in the company’s growing CDMO network. Three CDMO projects from external partners have already been secured for the expanded capacity, spanning oncology APIs, cardiovascular agents and central nervous system drugs. “This expansion reflects the growing demand for high-quality API manufacturing from partners who value reliability, regulatory compliance and scientific collaboration,” said Rajesh Patel, Site Director. “We are now one of the few facilities in India capable of manufacturing both conventional and highly potent APIs under a single roof.”
Espandiar Pharmaceuticals has established its first United States research and development center in Kendall Square, Cambridge, Massachusetts — the heart of the greater Boston biotechnology ecosystem. The 1,200-square-metre facility houses Espandiar’s US-based discovery biology team, computational science group and translational research unit, and serves as the company’s primary hub for clinical development operations in North America.
The Cambridge center focuses on three scientific areas. First, target discovery and validation, using CRISPR-based functional genomics, single-cell RNA sequencing and proteomics platforms to identify and validate new therapeutic targets in oncology and neurodegeneration. Second, computational and structural biology, leveraging the proximity to leading academic institutions (MIT, Harvard, the Broad Institute) and access to cryo-electron microscopy facilities for high-resolution protein structure determination. Third, translational medicine, supporting the company’s clinical programs with biomarker development, pharmacodynamic assay design and clinical data analysis capabilities.
“Opening our Cambridge R&D center is a strategic inflection point for Espandiar,” said Dr. Thomas Bergström, Chief Scientific Officer. “Kendall Square is the undisputed capital of biotechnology innovation, and being embedded in this ecosystem gives us access to an extraordinary concentration of scientific talent, academic collaboration opportunities and clinical research infrastructure. Our US presence also positions us to engage more effectively with the FDA and to participate in the vibrant venture and partnership landscape.” The center opened with an initial headcount of 35 scientists and is expected to grow to 80 within two years.
Espandiar Pharmaceuticals has announced the formal launch of its Contract Development and Manufacturing Organization (CDMO) services division, offering end-to-end API development and manufacturing capabilities to pharmaceutical and biotechnology partners worldwide. The new division leverages the company’s vertically integrated manufacturing infrastructure — including the Mumbai API facility, a newly established formulation and analytical development center in Berlin, and a network of qualified contract manufacturing partners — to provide a comprehensive range of services from route scouting and process development through commercial supply.
The CDMO service offering encompasses process research and development (route scouting, process optimization, technology transfer), analytical development (method development, validation and stability studies per ICH Q1A-Q2), GMP manufacturing of clinical trial materials (Phase I through Phase III) and commercial API supply, and regulatory support (DMF preparation, CMC documentation for IND/NDA/MAA submissions). A dedicated project management function provides single-point-of-contact oversight for each client engagement, with real-time visibility into project status through a secure client portal.
“Our CDMO launch is a natural extension of the manufacturing capabilities we have built over the past four years,” said Dr. Lukas Hartmann, CEO. “We believe that the pharmaceutical services market is increasingly seeking partners who combine deep scientific expertise with integrated manufacturing capabilities and a genuine commitment to quality. Our differentiation lies in our ability to apply the same rigour and innovation that drives our proprietary pipeline to the service of our partners’ programs.”
Espandiar Pharmaceuticals has closed a EUR 85 million Series B financing round, co-led by Wellington Management and T. Rowe Price Associates, with participation from existing investors EQT Ventures, Novo Holdings and Versant Ventures, and new investors including Fidelity Management & Research Company and the CPP Investments (Canada Pension Plan Investment Board). The round brings total capital raised to EUR 120 million since the company’s founding.
The Series B proceeds will fund a significant expansion of Espandiar’s clinical development activities, including the advancement of ESP-101 into a randomized Phase II study in biomarker-selected solid tumours, the initiation of two new first-in-human clinical trials for programs in neurology and rare disease, and the establishment of a clinical pharmacology unit for integrated pharmacokinetic-pharmacodynamic modelling and model-informed drug development (MIDD). A portion of the funds will also support continued investment in the AI-driven drug discovery platform and the expansion of CDMO manufacturing capacity.
“The calibre of investors participating in this round reflects the progress Espandiar has made and the confidence they have in our team, our science and our strategy,” said Dr. Lukas Hartmann, CEO. “With this financing, we have the resources to execute on our ambitious clinical plan while continuing to invest in the platform capabilities that will generate the next wave of pipeline programs. We are building a company designed for long-term value creation in pharmaceutical innovation.”
Espandiar Pharmaceuticals has announced the creation of a dedicated Biotechnology division and the formal launch of its monoclonal antibody (mAb) development platform. The new division, headquartered at the company’s Berlin-Buch campus with satellite operations in Cambridge, MA, will focus on the discovery, development and manufacturing of therapeutic antibodies, recombinant proteins and emerging modalities including antibody-drug conjugates (ADCs) and bispecific antibodies.
The platform is built on a suite of proprietary and licensed technologies, including a humanized phage display library containing over 100 billion unique antibody variable region sequences, a mammalian cell line development platform using CHO-K1 and CHO-DG44 host cells with glutamine synthetase (GS) and dihydrofolate reductase (DHFR) selection systems, and an integrated analytical characterization toolkit for comprehensive mAb quality assessment (peptide mapping, glycan profiling, charge variant analysis, size-exclusion chromatography and binding kinetics by surface plasmon resonance). The division has already advanced three antibody programs to lead optimization: a bispecific T-cell engager targeting CD3 and a tumour-associated antigen for oncology, a long-acting anti-inflammatory antibody for immunology, and an enzyme replacement therapy for a rare lysosomal storage disorder.
“The launch of our Biotechnology division represents a strategic expansion of Espandiar’s capabilities beyond small molecules,” said Dr. Thomas Bergström, CSO. “The biologics market is the fastest-growing segment of the pharmaceutical industry, and our ability to combine world-class antibody science with our existing small-molecule and CDMO capabilities creates a uniquely integrated platform. We are particularly excited about the potential of bispecific antibodies and ADCs, which represent the next wave of innovation in cancer therapy.”
Espandiar Pharmaceuticals has entered into a multi-year strategic research collaboration with the Dana-Farber Cancer Institute (DFCI) in Boston, Massachusetts, focused on the identification and validation of novel combination therapy regimens in precision oncology. The collaboration brings together Espandiar’s drug development capabilities with Dana-Farber’s world-renowned clinical and translational oncology research programs, creating a powerful framework for translating laboratory discoveries into clinical trials.
Under the terms of the agreement, Espandiar and Dana-Farber will jointly conduct preclinical studies using patient-derived organoid models and genetically engineered mouse models to evaluate rational drug combinations involving Espandiar’s clinical-stage and preclinical oncology candidates. The collaboration will also explore biomarker strategies for patient selection, using comprehensive genomic profiling (CGP) and single-cell technologies to identify molecular features that predict response or resistance to specific combination regimens. Dana-Farber will conduct the clinical components of the collaboration, including investigator-initiated trials and correlative science studies.
“Partnering with Dana-Farber — one of the world’s premier cancer research and treatment institutions — significantly enhances our ability to pursue innovative clinical development strategies in oncology,” said Dr. Elena Vasquez, CMO. “The combination of our emerging oncology pipeline with Dana-Farber’s deep clinical expertise and patient access creates a uniquely powerful platform for accelerating the development of new cancer treatments.”
Espandiar Pharmaceuticals has received its first marketing authorization from a national regulatory authority — the Pharmacy and Poisons Board of Kenya — for ESP-101 (to be marketed as “Esparib”), approving the product for the treatment of adult patients with germline BRCA-mutated advanced ovarian cancer who have progressed after two or more prior lines of platinum-based chemotherapy. The approval was based on data from Espandiar’s pivotal Phase II study (ESP-101-203), which demonstrated a confirmed objective response rate of 42.3% and a median progression-free survival of 7.8 months in the target population.
The Kenyan approval was pursued under a collaborative regulatory pathway that leveraged the African Medicines Regulatory Harmonisation (AMRH) initiative and the East African Community (EAC) harmonized registration guidelines. The dossier was prepared in CTD format and included comprehensive quality, non-clinical and clinical data modules. The approval also included conditions for a post-marketing pharmacovigilance plan, in accordance with the requirements of the Pharmacovigilance Centre of the Kenya Ministry of Health, and a commitment to conduct a local clinical study to generate additional data in the Sub-Saharan African patient population.
“Receiving our first marketing authorization is a proud moment for everyone at Espandiar,” said Dr. Katrin Becker, VP of Regulatory Affairs. “While our primary regulatory strategy is focused on the EMA and FDA, this approval in Kenya demonstrates our commitment to ensuring that patients in emerging markets have access to innovative medicines. We are now working on parallel submissions in additional African, Southeast Asian and Latin American markets.”
Espandiar Pharmaceuticals has completed the qualification and regulatory approval of its second API manufacturing facility, located in the Genome Valley pharmaceutical cluster in Hyderabad, India. The facility, which was acquired and extensively renovated over an 18-month period, adds dedicated capacity for high-potency API (HPAPI) manufacturing, including cytotoxic oncology APIs and hormone products requiring OEL-based containment below 1 μg/m³.
The Hyderabad facility features a fully enclosed containment system with operator isolation technology, negative-pressure HVAC with HEPA-filtered exhaust, continuous liner systems for all solid transfers, and pass-through autoclaves for waste decontamination. The quality control laboratory is equipped with UHPLC-QToF mass spectrometry, ICP-MS for elemental impurity testing (per ICH Q3D), and automated dissolution testing. The facility has received EU GMP certification, US FDA inspection readiness confirmation, and approvals from the CDSCO (India), TGA (Australia) and PMDA (Japan).
“The addition of our Hyderabad facility significantly expands our manufacturing capabilities and our addressable market,” said Marcus Lindberg, COO. “With two API sites in India plus our formulation capabilities in Berlin, we now have the infrastructure to support both our proprietary pipeline and a growing CDMO business. The Hyderabad site’s HPAPI capabilities are particularly valuable, as demand for highly potent oncology APIs continues to grow globally.”
Espandiar Pharmaceuticals has publicly committed to a comprehensive set of science-aligned environmental sustainability targets, including a pledge to achieve net-zero Scope 1 and Scope 2 greenhouse gas emissions by 2035 and a 50% reduction in absolute Scope 3 emissions by 2040, both from a 2019 baseline year. The targets have been validated by the Science Based Targets initiative (SBTi) as consistent with a 1.5°C warming pathway, making Espandiar one of the first mid-size pharmaceutical companies to receive SBTi validation.
The sustainability strategy, titled “Green Blueprint 2035,” encompasses four pillars: climate action (emissions reduction, renewable energy procurement, carbon offsetting for residual emissions), water stewardship (water consumption reduction, wastewater quality improvement, watershed protection in manufacturing regions), circular economy (solvent recovery, packaging reduction, waste-to-value initiatives), and biodiversity (responsible sourcing of raw materials, protection of natural habitats at manufacturing sites). Each pillar has defined near-term (2025), medium-term (2030) and long-term (2035) targets with measurable key performance indicators.
“As a science-based pharmaceutical company, it is entirely consistent with our values to ground our environmental commitments in science,” said Dr. Lukas Hartmann, CEO. “The SBTi validation confirms that our targets are aligned with what the latest climate science says is needed to avoid the most catastrophic impacts of climate change. We recognize that the pharmaceutical industry has a significant environmental footprint, and we are determined to do our part to reduce it — not through aspirational statements, but through measurable, accountable action.”
Espandiar Pharmaceuticals has launched a company-wide Green Chemistry Initiative (GCI) aimed at integrating the 12 Principles of Green Chemistry into every stage of its API development and manufacturing processes. The initiative, led by a newly formed Green Chemistry Council comprising senior scientists from process development, manufacturing, quality and EHS functions, establishes mandatory green chemistry metrics — including process mass intensity (PMI), E-factor, solvent recovery rate and carbon intensity per kilogram of product — as part of every project gate review.
Key elements of the GCI include a transition away from Class 1 and Class 2 ICH Q3C solvents (dichloromethane, NMP, DMF, chloroform) to greener alternatives (ethanol, 2-methyltetrahydrofuran, cyclopentyl methyl ether, water) in all new process development programs; the adoption of biocatalytic steps — using ketoreductases, transaminases and nitrilases — as the preferred approach for chiral synthesis, replacing traditional metal-catalyzed asymmetric reactions where feasible; the implementation of telescoped processes (eliminating intermediate isolation steps) and continuous flow chemistry for hazardous reactions, reducing solvent consumption, waste generation and safety risks; and the deployment of real-time environmental monitoring systems at all manufacturing sites to track and report green chemistry KPIs.
“Green chemistry is not an add-on or a marketing exercise — it is a fundamental requirement of responsible pharmaceutical manufacturing in the 21st century,” said Dr. Anika Müller, VP of Process Development. “By embedding green chemistry metrics into our decision-making processes from the earliest stages of development, we ensure that environmental considerations are not an afterthought but an integral part of how we design and optimize our processes.”
Espandiar Pharmaceuticals has completed the qualification of its first GMP biologics manufacturing line at the Berlin-Buch campus, marking the company’s entry into large-scale mammalian cell culture manufacturing. The 2,000-litre single-use bioreactor suite, designed in compliance with EU GMP Annex 1 and FDA guidance for biologics, supports the production of monoclonal antibodies, recombinant proteins and other biologics for both Espandiar’s proprietary pipeline and CDMO partners.
The facility features a multi-product single-use bioreactor train (200 L seed → 500 L expansion → 2,000 L production) with automated process control using a DeltaV distributed control system. Downstream processing includes depth filtration, Protein A affinity chromatography, mixed-mode polishing chromatography, viral inactivation (low pH hold), nanofiltration and ultrafiltration/diafiltration (UF/DF). The suite is designed for rapid changeover between products, with a target turnaround time of four weeks between campaigns. A dedicated fill-finish line for clinical trial material (vials and pre-filled syringes) is co-located within the same cleanroom complex.
The qualification campaign included three successful engineering runs and one GMP process validation run, all meeting pre-defined acceptance criteria for cell growth, product titer, product quality (purity, aggregation, glycan profile, charge variants) and process consistency. The facility has been inspected and approved by the German competent authority (PEI) and is now available for clinical and commercial manufacturing. “This milestone transforms Espandiar from a small-molecule company into a fully integrated pharmaceutical manufacturer spanning both chemical and biological modalities,” said Marcus Lindberg, COO.
Espandiar Pharmaceuticals has announced positive results from the Phase II portion of its ESP-101 clinical development program in biomarker-selected advanced solid tumours. The data were presented in an oral session at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, and simultaneously published in The Lancet Oncology.
The open-label, single-arm Phase II study (ESP-101-203) enrolled 186 patients with advanced solid tumours harbouring homologous recombination deficiency (HRD), as determined by next-generation sequencing using the Myriad myChoice CDx assay. The primary endpoint — objective response rate (ORR) by independent central review per RECIST v1.1 — was 41.4% (95% CI: 34.2–48.9), exceeding the pre-specified threshold for statistical significance (p < 0.001). Median duration of response was 12.7 months, and median progression-free survival was 8.4 months. Subgroup analyses showed particularly strong activity in patients with BRCA1/2-mutated ovarian cancer (ORR 54.2%) and PALB2-mutated breast cancer (ORR 48.7%).
The safety profile was manageable and consistent with the mechanism of action. The most common treatment-emergent adverse events (all grades) were nausea (38%), fatigue (34%) and anaemia (29%). Grade ≥ 3 adverse events occurred in 22% of patients, with the most frequent being anaemia (8%) and neutropenia (5%). No treatment-related deaths were reported. “These Phase II data confirm the hypothesis generated in our Phase I study and establish ESP-101 as a potentially best-in-class therapy for HRD-deficient cancers,” said Dr. Elena Vasquez, CMO. “We are now in active discussions with the EMA and FDA regarding the design of our Phase III confirmatory program.”
The European Medicines Agency (EMA) has granted a conditional marketing authorization (CMA) for Esparib (ESP-101) for the treatment of adult patients with germline BRCA1/2-mutated, HER2-negative advanced or metastatic breast cancer who have progressed after prior therapy including a taxane and an anthracycline. Esparib is Espandiar’s first product to receive regulatory approval in the European Union and represents the culmination of over five years of clinical development.
The conditional marketing authorization was granted based on the positive results of the Phase II ESP-101-203 study, which demonstrated a confirmed objective response rate of 41.4% and a median duration of response of 12.7 months in the biomarker-selected population. As a condition of the CMA, Espandiar has committed to completing the ongoing Phase III ESP-101-301 study — a randomized, controlled trial comparing Esparib plus physician’s choice chemotherapy versus physician’s choice chemotherapy alone in patients with germline BRCA-mutated advanced breast cancer — and to submit the final results as a post-authorization obligation.
“Today marks the most significant milestone in Espandiar’s history,” said Dr. Lukas Hartmann, CEO. “Receiving our first EMA approval is a testament to the dedication of our research, clinical development, regulatory and manufacturing teams, and to the courage of the patients who participated in our clinical trials. Esparib will now be available to patients across Europe who have limited treatment options. This is why we founded Espandiar — to turn scientific innovation into medicines that make a difference in patients’ lives.”
Espandiar’s CDMO division has launched a dedicated biologics contract manufacturing service offering, leveraging the company’s newly qualified 2,000-litre single-use bioreactor facility in Berlin. The service provides end-to-end support for biologics development and manufacturing, from cell line development and upstream process optimization through downstream purification, fill-finish and analytical characterization.
The biologics CDMO offering addresses a significant gap in the European contract manufacturing market, where demand for mammalian cell culture capacity has outpaced supply — a situation exacerbated by the growth of bispecific antibodies, ADCs and other complex biologic modalities. Espandiar’s service is differentiated by the integration of its AI-driven process development tools, including machine-learning models for predicting optimal cell culture conditions and chromatographic purification parameters, and its multi-attribute analytical platform, which provides comprehensive characterization of product quality attributes (glycosylation, charge variants, aggregates, sequence variants, post-translational modifications).
The division has already secured three CDMO partnerships for biologics manufacturing, including a European biotechnology company developing a bispecific antibody for haematological malignancies and a US-based gene therapy company requiring GMP-grade plasmid DNA and viral vector production support. “The expansion of our CDMO services into biologics is a natural evolution of our capabilities and a response to clear market demand,” said Lars Nilsson, SVP of CDMO Operations. “We are now one of the few European CDMOs that can offer integrated small-molecule and biologics manufacturing from a single partner.”
Espandiar Pharmaceuticals has officially opened its Asia-Pacific manufacturing and R&D campus in the Zhangjiang Hi-Tech Park in Shanghai, China. The 15,000-square-metre campus represents an investment of approximately EUR 65 million and includes an API manufacturing facility, a formulation development and clinical supply center, a quality control laboratory, and office and collaboration space for up to 250 employees.
The Shanghai facility has been designed and built to meet both Chinese NMPA and international (EU GMP, US FDA) manufacturing standards, enabling Espandiar to supply products to the Chinese domestic market and to use the facility as a manufacturing hub for the broader Asia-Pacific region. The facility includes multipurpose API synthesis reactors, an oral solid dosage form manufacturing line (tablets and capsules), and a dedicated clinical packaging and labelling suite. The on-site R&D center focuses on formulation development for the Chinese market (including adapted dosage forms to address local patient preferences) and analytical method development in support of regional regulatory submissions.
“The establishment of our Shanghai campus is a pivotal step in Espandiar’s globalization strategy,” said Dr. Lukas Hartmann, CEO, at the opening ceremony. “China is both one of the world’s largest pharmaceutical markets and a critical node in the global pharmaceutical supply chain. This campus positions us to serve Chinese patients directly, to support our CDMO partners with regional manufacturing capacity, and to tap into China’s extraordinary scientific talent pool. We are committed to being a long-term, responsible corporate citizen in China.”
Espandiar Pharmaceuticals has dosed the first patient in a Phase I/II clinical trial of ESP-4821, a novel enzyme replacement therapy for the treatment of a rare lysosomal storage disorder (LSD). The study, designated ESP-4821-001, is being conducted at four specialist clinical sites in Europe and is the first clinical trial to emerge from Espandiar’s Rare Disease therapeutic area, established in 2022.
ESP-4821 is a recombinant human enzyme conjugated to a proprietary glycan-targeting moiety that enhances cellular uptake via the mannose-6-phosphate receptor (M6PR). Preclinical data, published in Nature Communications, demonstrated superior tissue distribution and intracellular enzyme activity compared to the existing standard of care, including a 3.8-fold increase in enzyme activity in the brain parenchyma — a critical advantage given the CNS involvement typical of this disorder. The Phase I/II study is an open-label, dose-escalation and dose-expansion trial that will enroll approximately 24 patients across three dose levels, with primary endpoints of safety, tolerability and pharmacokinetics, and secondary endpoints including biomarker responses (lysosomal substrate levels in cerebrospinal fluid and plasma) and exploratory clinical efficacy measures.
“Initiating the first clinical trial for our rare disease program is a deeply meaningful moment for our team and for the patient community we serve,” said Dr. Maria Fernandez, Head of Rare Disease Research. “Lysosomal storage disorders are devastating diseases with very limited treatment options, and patients and families have waited too long for new therapies. The preclinical data for ESP-4821 give us confidence that this approach has the potential to make a meaningful difference, and we are committed to developing it with the urgency that rare disease patients deserve.”
Espandiar Pharmaceuticals has initiated patient enrollment in ESP-101-301, a pivotal Phase III, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Esparib (ESP-101) in combination with physician’s choice chemotherapy versus chemotherapy alone in patients with germline BRCA1/2-mutated, HER2-negative metastatic breast cancer. The study is the confirmatory trial required under the conditions of Esparib’s conditional marketing authorization granted by the EMA in 2024.
The global study plans to enroll approximately 420 patients across 120 clinical sites in 18 countries across Europe, North America, Asia-Pacific and Latin America. The primary endpoint is progression-free survival (PFS) as assessed by blinded independent central review per RECIST v1.1. Key secondary endpoints include overall survival (OS), objective response rate (ORR), duration of response (DoR), patient-reported outcomes (using the EORTC QLQ-C30 and BR23 questionnaires) and safety. An adaptive design feature allows for pre-specified interim analyses for efficacy and futility using an O’Brien-Fleming alpha-spending function, with the potential to stop the trial early for overwhelming efficacy.
“The initiation of our Phase III study is a critical step toward full marketing authorization for Esparib in the EU and toward our first NDA submission to the FDA,” said Dr. Elena Vasquez, CMO. “We have designed ESP-101-301 to be a rigorous, globally representative trial that will generate the high-quality evidence needed to support regulatory approvals worldwide. We are grateful to the investigators, site staff and patients who are participating in this important study.”
Espandiar Pharmaceuticals has entered into a multi-year strategic collaboration with a top-10 global pharmaceutical company for the co-development and co-commercialization of a novel precision oncology program targeting KRAS G12C-mutant non-small cell lung cancer (NSCLC). Under the terms of the agreement, Espandiar will receive an upfront payment of EUR 150 million, up to EUR 850 million in milestone payments contingent on development, regulatory and commercial achievements, and tiered royalties on future net sales.
The collaboration centers on ESP-7021, a next-generation, brain-penetrant KRAS G12C inhibitor that has demonstrated differentiated preclinical and early clinical activity compared to first-generation KRAS G12C inhibitors. In the ongoing Phase I/II ESP-7021-001 study, ESP-7021 has shown confirmed objective responses in patients with NSCLC, including patients with untreated brain metastases — a population that is poorly served by current therapies due to limited blood-brain barrier penetration of existing KRAS inhibitors. The companies will jointly conduct the planned global Phase III program, share development costs and co-commercialize the product in agreed territories.
“This collaboration is a powerful validation of Espandiar’s scientific capabilities and a transformative event for our company,” said Dr. Lukas Hartmann, CEO. “Partnering with a global leader brings complementary expertise in large-scale clinical development, regulatory strategy and commercialization that will accelerate the delivery of ESP-7021 to patients worldwide. The upfront and potential milestone payments also significantly strengthen our financial position, providing the resources to advance our broader pipeline while maintaining our commitment to building a fully integrated pharmaceutical company.”
Espandiar Pharmaceuticals has completed the deployment of its proprietary AI-powered predictive manufacturing system, codenamed “Sentinel,” across all eight of its manufacturing sites worldwide. Sentinel integrates real-time sensor data from manufacturing equipment (reactor temperature, pressure, agitation, pH, dissolved oxygen, off-gas composition) with batch record data, environmental monitoring data and supply chain information to provide predictive insights that enable proactive decision-making and continuous process improvement.
The system uses a combination of supervised machine learning models (trained on historical batch data to predict critical quality attributes and detect anomalous patterns) and unsupervised anomaly detection algorithms (which identify novel patterns that deviate from expected process behaviour without requiring labeled training data). Key capabilities include predictive batch release, which uses real-time process data to predict whether a batch will meet final release specifications before testing is complete — reducing batch cycle time by an estimated 15–20%; predictive maintenance, which analyzes equipment sensor data to forecast failures before they occur, reducing unplanned downtime; and real-time process optimization, which provides operators with recommendations for adjusting process parameters to maximize yield and quality.
“Sentinel represents the convergence of our AI capabilities with our deep manufacturing expertise,” said Prof. Henrik Larsson, VP of Computational Chemistry and Digital Manufacturing. “By applying machine learning to the vast quantities of data generated during pharmaceutical manufacturing, we can move from reactive quality control to predictive quality assurance — catching potential deviations before they result in out-of-specification batches, optimizing processes in real time, and ultimately improving both product quality and manufacturing efficiency. This is the future of pharmaceutical manufacturing, and Espandiar is leading the way.”
Espandiar Pharmaceuticals has reported updated results from the Phase II portion of the ESP-7021-001 study, demonstrating clinically meaningful intracranial antitumour activity in patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC) and untreated brain metastases. The data, presented in a late-breaking oral session at the IASLC World Conference on Lung Cancer, represent a potential breakthrough for a patient population with very limited treatment options.
In the pre-specified intracranial efficacy cohort (n=42), ESP-7021 achieved an intracranial objective response rate (iORR) of 52.4% by RANO-BM criteria, with 8 patients achieving a complete intracranial response. Median intracranial duration of response was 14.3 months, and median intracranial progression-free survival was 11.8 months. Concentrations of ESP-7021 in cerebrospinal fluid (CSF) exceeded the in vitro IC90 for KRAS G12C inhibition by a median of 4.2-fold, confirming robust blood-brain barrier penetration. Systemic efficacy was also compelling, with an overall ORR of 48.1% and median PFS of 9.6 months in the full Phase II population (n=128).
“These intracranial data are unprecedented for a KRAS G12C inhibitor and address one of the most significant unmet needs in NSCLC,” said Dr. Elena Vasquez, CMO. “Brain metastases develop in approximately 30–50% of patients with advanced NSCLC and are associated with very poor prognosis. The ability of ESP-7021 to achieve meaningful intracranial responses — including complete responses — while maintaining systemic activity positions this program as a potential new standard of care. We are working with our collaboration partner to accelerate the initiation of the Phase III program.”
Espandiar Pharmaceuticals has announced a significant advancement in its precision oncology pipeline with the progression of ESP-7021, a next-generation, brain-penetrant KRAS G12C inhibitor, into late-stage clinical development. The decision follows a comprehensive review of Phase II data by an independent data monitoring committee, which confirmed that ESP-7021 met all pre-specified criteria for progression, including robust systemic and intracranial efficacy, a manageable safety profile and favorable pharmacokinetic-pharmacodynamic relationships across the evaluated dose range.
ESP-7021 is a differentiated small-molecule inhibitor of the KRAS G12C oncoprotein, which is the most common KRAS mutation in non-small cell lung cancer (NSCLC), accounting for approximately 13% of all NSCLC cases globally. Unlike first-generation KRAS G12C inhibitors, ESP-7021 was specifically designed for enhanced central nervous system penetration, addressing a critical gap in the treatment of NSCLC patients who develop brain metastases — a population that represents approximately 30–50% of advanced NSCLC cases and has historically had very limited therapeutic options. In the completed Phase II study (ESP-7021-001), ESP-7021 demonstrated an intracranial objective response rate of 52.4% by RANO-BM criteria in patients with untreated brain metastases, with cerebrospinal fluid concentrations exceeding the IC90 for KRAS G12C inhibition by more than four-fold.
The planned global Phase III program, conducted in collaboration with Espandiar’s strategic partner, will evaluate ESP-7021 versus standard-of-care therapy in two parallel pivotal studies: one in first-line KRAS G12C-mutant NSCLC (including patients with stable brain metastases), and a second in second-line NSCLC with untreated brain metastases. The combined Phase III program is expected to enroll approximately 1,200 patients across 250 clinical sites in 25 countries, making it the largest clinical trial in Espandiar’s history. The first patient in the Phase III program is expected to be enrolled in the fourth quarter of 2026.
“The advancement of ESP-7021 to late-stage development is a defining moment for Espandiar and for the patients we aim to serve,” said Dr. Lukas Hartmann, CEO. “This program embodies our precision medicine philosophy — developing targeted therapies for molecularly defined patient populations, using biomarkers to match the right drug to the right patient, and designing clinical trials that generate the evidence needed to change clinical practice. ESP-7021 has the potential to redefine the treatment landscape for KRAS-mutant lung cancer, particularly for patients facing the devastating diagnosis of brain metastases.”
Artificial intelligence has fundamentally transformed the early stages of drug discovery, moving from a niche academic curiosity to a core capability within leading pharmaceutical R&D organisations. At Espandiar, our AI-guided drug discovery platform integrates multi-modal data streams — including genomics, proteomics, chemical structure databases, real-world evidence from electronic health records, and published scientific literature — to identify stronger therapeutic hypotheses with greater speed and confidence than traditional approaches.
The platform employs a layered architecture. At the foundation, large-scale knowledge graphs encode relationships between genes, proteins, pathways, diseases, compounds and clinical observations, enabling hypothesis generation through graph-based reasoning. Above this, machine learning models — including graph neural networks for molecular property prediction, transformer-based models for protein structure understanding, and generative models for de novo molecular design — provide quantitative predictions that guide experimental design. The top layer is an active-learning system that iteratively prioritises experiments based on expected information gain, ensuring that every experiment conducted contributes maximally to the project’s knowledge base.
Virtual screening — the computational evaluation of millions to billions of chemical structures against a biological target — is one of the most mature applications. Espandiar’s virtual screening pipeline uses a combination of structure-based methods (molecular docking with physics-based scoring functions, enhanced by deep learning re-scoring) and ligand-based methods (similarity searching, pharmacophore modelling and quantitative structure-activity relationship modelling) to identify promising hit compounds from libraries exceeding 10 billion enumerated structures.
The emergence of AlphaFold and subsequent protein structure prediction tools has been particularly impactful. Where previously the 3D structure of a target protein was a bottleneck — requiring months or years of experimental determination by X-ray crystallography or cryo-electron microscopy — high-confidence predicted structures are now available for the entire human proteome. This democratisation of structural biology has enabled Espandiar to initiate structure-based drug design campaigns against targets that were previously considered “undruggable” due to the absence of structural data.
Looking forward, Espandiar is investing in quantum computing applications for molecular simulation, federated learning approaches that enable multi-institutional collaboration without sharing proprietary data, and the integration of patient-derived data (organoids, single-cell profiles, digital biomarkers) to ensure that AI-generated hypotheses are grounded in human biology from the outset.
Predictive clinical design represents the application of quantitative models, digital technologies and patient-centric data to plan and execute clinical trials with greater precision and efficiency. At Espandiar, this approach is embedded across our clinical development organisation and spans the entire trial lifecycle — from first-in-human dose selection through confirmatory Phase III studies and post-marketing commitments.
Model-informed drug development (MIDD) is a cornerstone of our predictive approach. Using physiologically based pharmacokinetic (PBPK) models, population pharmacokinetic-pharmacodynamic (PopPK-PD) models, and quantitative systems pharmacology (QSP) models, we simulate drug behaviour across diverse patient populations before committing to clinical study designs. These simulations inform dose selection, predict drug-drug interaction risk, optimise sampling schedules and estimate the probability of technical success for different trial designs. By front-loading quantitative analysis, we reduce the number and size of clinical studies required and increase the probability of success in pivotal trials.
Digital biomarkers — collected through wearable sensors, smartphone-based assessments and remote monitoring devices — provide continuous, real-world data on patient function and disease progression that traditional clinic-based assessments cannot capture. Espandiar is incorporating digital endpoints into clinical trials across neurology, cardiology and rare diseases, where the episodic nature of clinic visits may miss important fluctuations in disease activity. Wearable-derived measures of gait, tremor, heart rate variability and sleep architecture are being qualified as secondary and exploratory endpoints, with the long-term goal of enabling hybrid trial designs that combine in-clinic and remote assessments.
Adaptive trial protocols, designed with pre-specified decision rules and interim analyses, allow us to modify trial parameters in response to accumulating data — adjusting sample size, dropping ineffective arms, enriching for responder subpopulations, or combining Phase II and Phase III objectives into a single seamless study. These designs are particularly valuable in our oncology and rare disease programs, where patient populations are limited and efficient use of every data point is essential.
Our commitment to predictive clinical design is driven by a simple principle: every clinical trial should be designed around the patient’s journey, informed by the best available quantitative evidence, and optimised to deliver a definitive answer with the minimum burden on participants. This approach not only accelerates development timelines — it also generates higher-quality evidence that supports regulatory approval and clinical decision-making.
Connected therapeutics is Espandiar’s vision for the future of medicine — an approach that combines pharmaceutical products with digital care tools, remote monitoring and data-driven clinical decision support to deliver more responsive, individualized treatment. Rather than viewing the drug as an isolated intervention, connected therapeutics considers the medicine as part of a broader care ecosystem that includes the patient, the healthcare provider, the care team and digital infrastructure.
At the core of this approach is the integration of digital health technologies with pharmaceutical products. For patients on chronic therapies — such as those in our neurology and cardiometabolic portfolios — adherence is one of the most significant determinants of treatment outcomes. Connected packaging (smart blister packs with embedded sensors), medication event monitoring systems and mobile health applications can provide real-time visibility into patient adherence patterns, enabling timely interventions by pharmacists, nurses or physicians when adherence drops below a pre-defined threshold.
Remote patient monitoring extends the care relationship beyond the clinic visit. Wearable biosensors and home-based diagnostic devices can track physiological parameters — blood glucose, blood pressure, heart rate, respiratory rate, SpO2, body temperature and activity levels — and transmit this data securely to the care team through cloud-based platforms. For patients in our clinical trials, remote monitoring reduces the frequency of clinic visits, lowers the burden of participation, and generates richer, more continuous data on treatment response and disease progression. For patients in routine clinical care, remote monitoring enables early detection of deterioration, timely dose adjustments and proactive management of adverse events.
Clinical decision support systems (CDSS), powered by machine learning algorithms trained on real-world data from Espandiar’s patient registries and clinical trial databases, provide personalised treatment recommendations to physicians. These systems can predict which patients are most likely to benefit from a particular therapy, identify patients at risk of developing specific adverse events, and suggest optimal dosing regimens based on patient characteristics, concomitant medications and genetic factors. By embedding evidence-based decision support into the clinical workflow, connected therapeutics aims to close the gap between the efficacy observed in clinical trials and the effectiveness achieved in routine practice.
Espandiar is actively investing in the digital infrastructure, partnerships and regulatory capabilities required to bring connected therapeutics to patients. Our collaborations with digital health companies, academic medical centres and patient advocacy organisations ensure that our connected therapeutics programmes are designed with the patient at the centre — not as a technology-first exercise, but as a care-first transformation of how medicines are delivered, monitored and optimised throughout the treatment journey.